Analyst Michael Matson of Needham maintained a Buy rating on Insight Molecular Diagnostics, retaining the price target of $9.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Matson has given his Buy rating due to a combination of factors tied to Insight Molecular Diagnostics’ lead transplant product. He highlights new analytical validation data presented at the CEoT 2026 Summit, where GraftAssureIQ showed substantially faster turnaround than a prominent NGS-based competitor while maintaining strong agreement in results, underscoring both clinical relevance and operational advantages.
He also points to key differentiators such as same-day reporting, flexible single-sample processing, and attractive reimbursement prospects for hospitals, which together enhance the test’s adoption potential and economic value. In addition, the intention of Tampa General Hospital to bring GraftAssure in-house by summer 2026 supports Matson’s view that IMDX is advancing meaningfully toward the clinical launch of GraftAssureDx, making 2026 a likely inflection year for the company’s growth trajectory.
According to TipRanks, Matson is a 3-star analyst with an average return of 1.7% and a 45.22% success rate. Matson covers the Healthcare sector, focusing on stocks such as TransMedics Group, Teleflex, and Atricure.
In another report released today, Lake Street also reiterated a Buy rating on the stock with a $12.00 price target.